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ess: bcelli@copdnet.orgSummary The pathophysiology of chronic obstructive pulmonary disease (COPD) is
complex. The development of a multidimensional index—such as the BODE
index—provides a means of classifying patients with COPD that also correlates with
their prognosis. The individual components of the BODE index—body mass index (B),
airflow obstruction (O) dyspnoea (D) and exercise capacity (E)—incorporate the
pulmonary as well as the systemic effects seen in patients with COPD. Recent
research has focussed on examining these impairments (including those of
metabolism and inflammation) more carefully, and determining the effects of
treatment on both the systemic and physiological aspects of COPD.
Ongoing research initiatives by the public and private sector will contribute to our
understanding of the disease processes underlying COPD, our understanding of the
benefits associated with commonly used pharmacotherapies, as well as laying the
foundations for the development of new agents and therapeutic tools. Advances in
the use of pharmacotherapy have been mirrored by research to better define the
benefits associated with pulmonary rehabilitation. Many questions remain to be
answered, but a comprehensive approach is now considered essential to the life-long
management of COPD, and will undoubtedly reduce the considerable socio-economic
burden of COPD.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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According to the 2004 update of the WHO world
health report, chronic obstructive pulmonary dis-
ease (COPD) was the fifth most common cause of
death in 2002 (4.8% of deaths)—only ischaemic
heart disease (12.6% of deaths), cerebrovascular
disease (9.7%), lower respiratory infections (6.8%)
and HIV/AIDS (4.9%) were more common causes of
death worldwide.1 Clearly therefore, COPD imposes
a huge socio-economic burden on both the indivi-
dual and society. Novel modes of therapy will have
to be developed, and our current array of treat-
ments utilised to their fullest extent, to further
reduce the chronic burden of this disease on the
patient, and ultimately, improve long-term survi-
val. Examples include more efficient smoking
cessation strategies, targeted pharmacological
therapies, and the incorporation of pulmonary
rehabilitation into the life-long management of
individuals with chronic respiratory disease.2
Furthermore, the initiation of large pharmaceutical
trials specifically designed to evaluate disease
modification or a survival advantage will have a
major impact on our understanding of COPD and its
treatment.3 It is clear that chronic airflow limita-
tion is only the most obvious manifestation of a
disease that is also characterised by systemic
inflammation,4 oxidative stress5 and muscular
weakness.6 Our better understanding of how these
and other disease processes impact on well-being
and survival will almost certainly lead to better
outcomes.Towards a better appreciation of the
pervasive nature of COPD
The physiological hallmark typically used now to
define COPD—a reduction in forced expiratoryTable 1 The BODE index—four variables identified as b
the values (0–3) assigned to each variable by category.8
Variable Points on the
0
B—Body mass index (kg/m2) 421
O—FEV1 (% of predicted)
y X65
D—Distance walked in 6min (m) X350
E—MMRC dyspnoea scale (score) 0–1
FEV1, forced expiratory volume in 1 s; MMRC, modified Medical R
Values for body mass index are 0 or 1 owing to the inflection po
index at a value of 21 kg/m2.
yFEV1 categories are based upon stages identified by the Amervolume in 1 s (FEV1)—underscores the importance
of progressive airway obstruction in this disease.7
However, COPD clearly has complex pathophysiol-
ogy, and other factors must be considered in
evaluating its effect on patients. The BODE index,
published in 2004,8 is a multidimensional scoring
system designed to this effect. The index was
developed by examining a cohort of 207 patients
with COPD for factors predictive of death. Four
factors were identified—body mass index (B),
airflow obstruction (O), dyspnoea (D) and exercise
capacity (E). Measurements of each variable were
assigned scores (Table 1), such that summing the
scores together would give an index of disease
severity—the BODE index. This scoring is strongly
predictive, not only for respiratory death, but also
for death from any cause,8 and its scoring by
quartiles is more predictive of survival than the
three-stage American Thoracic Society (ATS) spiro-
metric staging (Fig. 1).9 The predictive power of
the BODE index arises from incorporating four
domains that are strongly informative for different
aspects of the health of patients with COPD.
Clearly, airflow limitation is critical in evaluating
COPD. FEV1 has long been known to reflect under-
lying airflow limitation in COPD, and is a good
marker for disease progression.7 However, FEV1
measurement is not a good surrogate for measure-
ment of dyspnoea—the predominant symptom in
COPD, and a stronger predictor of mortality than
the FEV1.
10,11 Dyspnoea can be reliably and
accurately assessed using unidimensional or multi-
dimensional scales.7
Over the previous decade, there has been an
increasing appreciation of the importance of the
systemic manifestations of COPD.12 These include
muscular weakness and alterations in body mass
index (BMI), both of which are related to survival in
patients with COPD.13,14 The effect of nutritional
depletion on survival was demonstrated in a study
published by Schols et al. in 1998.13 In this study,eing predictive of survival in patients with COPD, and
BODE index
1 2 3
p21 — —
50–64 36–49 p35
250–349 150–249 p149
2 3 4
esearch Council.
int in the inverse relationship between survival and body mass
ican Thoracic Society.
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Figure 1 (A) Kaplan–Meier survival curves for the four
quartiles of the BODE index and (B) for the three stages
of severity of COPD as defined by the American Thoracic
Society.8
Future perspectives in COPD S43stratifying patients (N ¼ 400) with COPD into BMI
quintiles revealed a threshold value for BMI of
25 kg/m2, below which there was a clear increase in
the risk of mortality.13 Patients with COPD also have
weak respiratory and peripheral muscles,6 with
muscular weakness being linked to reduced survi-
val.14 Indeed, Marquis et al.14 in 2002, showed that
mid-thigh cross-sectional area (MTCSA) is strongly
predictive of mortality, and has a particularly
strong impact on survival in patients with an
FEV1o50%. Furthermore, reduced muscular
strength is likely a reflection of patient functional
or exercise capacity, and can be measured using the
6-min walk test. Pinto-Plata et al.15 showed that,
during a 2-year observation of 198 patients with
severe COPD, there were greater reductions in the
distance walked in 6min among the patients who
died. In fact, the 6-min walk test predicted
mortality better than FEV1 measurements.Although muscular weakness (MTCSA), exercise
capacity (6-min walk test) and BMI are interrelated,
and are likely to share some of the underlying
determinants, they indicate different aspects of
the pathophysiology of COPD, and are independent
predictors of mortality.13,15–17 In particular, the 6-
min walk test contains a degree of sensitivity not
provided by measurements of BMI. The inclusion of
both BMI and 6-min walk test measures in the BODE
index, ensures that the final BODE score strongly
reflects the pathophysiological effects of COPD on
the patient.8New paradigms in COPD therapy
Targeting lung hyperinflation in COPD
Static and dynamic lung hyperinflation—common
physiologic derangements in COPD—are important
determinants of exertional dyspnoea,18 with emer-
ging evidence linking hyperinflation to mortality. In
a 2004 study of 689 patients with stable COPD by
Casanova et al., lung hyperinflation was a signifi-
cant predictor of mortality. Inspiratory capacity
(IC) was used as an indirect measure of hyperinfla-
tion, because in the absence of a change in the
total lung capacity (TLC), a decrease in IC indicates
an increase in end-expiratory lung volume or
hyperinflation. Those patients with an IC/TLC ratio
40.25 had significantly greater cumulative survival
(all cause or respiratory failure) over the course of
4 years (Fig. 2), compared with an IC/TLCp0.25
(Po0:0001).19 If hyperinflation is truly associated
with increased mortality, then targeting this
physiologic abnormality may prove a useful target
for future treatment paradigms.
Bronchodilators, both short- and long-acting,
have been shown to reduce hyperinflation in
patients with COPD. In a trial reported by Celli et
al.18 tiotropium was associated with significant
(Po0:05) reductions in inspiratory capacity and
thoracic gas volume over 4 weeks. Similar results
have been shown with the long-acting b2-agonist
salmeterol.20
Lung-volume-reduction surgery (LVRS) is another
means of reducing hyperinflation, and the relation-
ship between LVRS and survival was examined
recently in the National Emphysema Treatment
Trial. This study examined the effects of LVRS usual
medical care (pulmonary rehabilitation) in 1218
patients with severe emphysema.21 Subgroup ana-
lysis showed that surgery had the greatest survival
benefit for those patients with both predominantly
upper-lobe emphysema and low baseline exercise
ARTICLE IN PRESS
Figure 2 Cumulative survival (4-year) of patients with
stable COPD and an inspiratory capacity/total lung
capacity (IC/TLC) 40.25, versus patients with stable
COPD and an IC/TLCp0.25. Kaplan–Meier survival curves
for (A) all causes and (B) respiratory failure.19
B. Celli et al.S44capacity. Therefore, while LVRS can prolong survi-
val in COPD, this beneficial outcome is restricted to
a carefully selected group of patients.
Targeting the systemic effects of
COPD—molecular insights
The use of long-term oxygen therapy has been
shown to improve life expectancy in COPD.22,23 This
therapy does not modify the degree of airflow
limitation and therefore provides hard evidence
that it is not absolutely necessary to change lungfunction to improve outcomes in COPD. Indeed,
more recent studies have provided a molecular
basis for, and insight into, the benefits associated
with therapies that are directed at the systemic
manifestations of the disease, rather than at
altering lung function.
A number of studies have demonstrated that
patients with COPD have systemic metabolic
defects. Maltais et al. examined arterial lactic acid
concentrations and the oxidative capacity of
skeletal muscle during exercise in nine patients
with COPD. Compared with control subjects,
patients with COPD had significantly (Po0:0005)
reduced levels of oxidative enzymes, as well as
significantly (Po0:0005) increased levels of lactic
acid.24 Sauleda et al.25 also showed that patients
with chronic respiratory failure and COPD have
increased respiratory-muscle mitochondrial cyto-
chrome oxidase activity relative to normal sub-
jects. Taken together, these results suggest that,
compared with normal subjects, muscular tissue in
patients with COPD is fundamentally less able to
process metabolic precursors and waste products
and, consequently, is more readily subjected to
metabolic oxidative stress during exercise. These
observations are clearly related to the respiratory
and peripheral muscular weakness experienced by
patients with COPD. Of note, such molecular
observations have a very real bearing on the
outcome of the patient—in 2004, Montes de Oca
et al.26 published the results of a study showing a
relationship between markers of oxidative stress
(nitrite, nitrate and nitrotyrosine) and the BODE
index.
Further evidence of the systemic consequences
of COPD is provided by the unexplained weight loss
that is observed in 30–50% of patients with
COPD—a contributory cause of mortality.27 This
weight loss has been shown to be associated with
levels of tumour necrosis factor-alpha (TNF-a)—an
inflammatory mediator shown to cause cachexia in
laboratory animals.28 A study published by Di
Francia et al.29 in 1994 examined the relationship
between serum TNF-a levels and body weight in 30
patients with stable COPD. Those patients with a
mean body weight 81% of normal had 10-fold higher
levels of TNF-a (70.2 pg/mL), compared with
patients who had a mean body weight of 121% of
normal (TNF-a ¼ 6.7 pg/mL; P ¼ 0:0001). Hence,
TNF-a is clearly a contributory factor to weight
loss, muscular weakness and reduced BMI in these
patients. In a different study, Sin et al.30 demon-
strated that fluticasone propionate substantially
(71%; P ¼ 0:039) reduces the levels of C-reactive
protein—a well-known marker of inflammation.
This observation is extremely important because it
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not all, of the markers of systemic inflammation,
and, if confirmed, could open new avenues of
therapy.
It will become increasingly important in the
future to develop new treatment paradigms that
make full use of our knowledge of the pathophy-
siology of COPD, so that we are better able to treat
the effects of this disease and assess how beneficial
these treatments are for the patient.New pharmaceutical industry initiatives
for COPD
With expansion of our knowledge of the pathophy-
siology of COPD, we are better able to characterise
and manage patients with this disease. Paralleling
such advances are new means of identifying those
at risk of COPD, as well as new treatments to
modify the course of this condition.
The international COPD genetics network
Initiatives are underway to clarify disease mechan-
isms, permitting better phenotypic characterisa-
tion and, ultimately, encouraging the discovery and
development of new disease-modifying drugs. One
of the most important of these initiatives—The
International COPD Genetics Network (sponsored
by GlaxoSmithKline)—has enrolled 3500 patients
(and in many cases their siblings) across 10
investigative sites, into a family-based study, to
identify susceptibility genes for COPD. Extensive
genetic and phenotypic data have been collected
from study participants so as to better define the
manifestations of COPD and to help characterise
intermediate phenotypes. Analysis of phenotypic
and genetic data should assist with the identifica-
tion of patients at risk of COPD and the prediction
of patient response to treatment.
As part of the Genetics Network initiative, new
tools to characterise the anatomical and mechan-
istic changes associated with COPD are being
developed. For example, patients in the network
will undergo high-resolution computed tomography
scans, the data being used to validate this
technique and also to provide greater discrimina-
tion of the different phenotypic aspects of COPD
(e.g. airway disease versus parenchymal disease),
so that the effects of treatment can be more
precisely defined. This could prove important in
demonstrating efficacy of treatment when changes
in lung function as measured by spirometry may not
be detectable. Other tools in development includethe use of inhaled hyperpolarised gas to aid in
producing three-dimensional images of the lung.
These images can be used to provide important
measurements of lung dimensions, so that through
the comparison of multiple images from the same
patient over time, a more dynamic assessment of
their disease progression and the effect of treat-
ment are obtained.Defining the benefits of COPD
pharmacotherapy—key trials
Randomised clinical trials have established the
benefits of long-term home oxygen therapy on
survival in COPD.31 While the benefits of pharma-
cotherapy in reducing airflow limitation and ex-
acerbations have been well established in COPD,
improvements in survival and in the rate of decline
in FEV1 are now the subject of important prospec-
tive trials.TORCH—TOwards a revolution in COPD health
TORCH is a landmark multicentre, randomised,
double-blind, parallel-group, placebo-controlled
study, which is designed to establish the effect on
survival of fluticasone propionate (steroid) and
salmeterol (long-acting b2-agonist) individually or
in combination.3 The primary end point is all-cause
mortality; secondary end points are COPD morbid-
ity relating to rate of exacerbations, and health
status assessed using the St. George’s Respiratory
Questionnaire.32 The trial was initiated in 2000,
and results are expected in 2006. The data from
this large, randomised trial in over 6000 patients
from 42 countries, will prospectively examine
findings from previous observational studies and
post hoc analyses, which demonstrated improve-
ment in survival with inhaled steroids and long-
acting b2-agonists in patients with COPD.UPLIFT—understanding potential long-term
impacts on function with tiotropium
UPLIFT is a multicentre, randomised, double-blind,
parallel-group, placebo-controlled study, that is
designed to establish whether tiotropium can
reduce the rate of lung function decline (pre and
post-bronchodilator FEV1 from 30 days to study
completion), health status and exacerbation fre-
quency in patients with COPD.33 The trial was
initiated in 2003 and the results are expected in
2008. The data from this large randomised trial in
over 6000 patients from 35 countries is important
because, to date, no pharmacological intervention
has conclusively shown such benefits.
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awaited, as they will undoubtedly enhance our
understanding of the long-term effect of treatment
on the natural history of COPD.The future of pulmonary rehabilitation
Pulmonary rehabilitation—early myths
refuted
The emergence of pulmonary rehabilitation over
the past 15 years as a gold standard of care, and its
prominent placement in recent COPD guidelines has
come following the refutation of a number of myths
in the medical community. These myths include,
firstly, the assumption that little can be done to
address the physiological impairments of COPD;
secondly, that since pulmonary rehabilitation has
little effect on airflow limitation it cannot have
appreciable beneficial effect on the patient;
thirdly, that since their condition is largely self-
induced through smoking, nothing should be done
to assist these patients; and finally, that in the
latter stages of COPD the prognosis is invariably
poor. These misconceptions have given way to a
more comprehensive approach to the treatment of
these patients, and the realisation that even
severely affected patients can still enjoy appreci-
able survival as well as health-related quality of
life.2
Other prevailing myths were that comorbidities
are a contraindication for pulmonary rehabilita-
tion; that non-physicians have a very limited role;
and that the goals of rehabilitation were best
defined by healthcare professionals. On the con-
trary, the appropriate management of the patient’s
comorbidities reduces their effect on exercise
intolerance, and pulmonary rehabilitation is best
administered by an inter-disciplinary team, incor-
porating a collaborative approach where the
patient is integrally involved in determining their
own rehabilitation intervention.2
The perception that pulmonary rehabilitation is
expensive was one of the easier myths to refute.
Two recent studies published by Bourbeau et al.34
in 2003 and Griffiths et al.35 in 2000, showed that
pulmonary rehabilitation significantly decreases
the use of health care services. In the former
study, patients with advanced COPD were rando-
mised to receive usual care (n ¼ 95) or a home-
based programme of education and self-manage-
ment (n ¼ 95) once per week for 2 months, with 1
year of follow-up. Compared with usual care,
patients receiving the education programme had a39.8% (P ¼ 0:01) reduction in hospital admissions
for exacerbations and a 57.1% (P ¼ 0:01) reduction
in admissions for other health problems.34 In
addition, emergency department visits and un-
scheduled physician visits were reduced by 41.0%
(P ¼ 0:02) and 58.9% (P ¼ 0:003), respectively.
Similar results were seen in a study by Griffiths et
al.35 In this study, 200 patients with disabling COPD
(FEV1o60% of predicted) were assigned to a 6-
week rehabilitation programme or standard medi-
cal management, and were followed up for 1 year.
Those patients receiving rehabilitation spent 50%
less time in hospital (mean of 10.4 days versus 21.0
days; P ¼ 0:022) and had fewer primary care home
visits (1.5 versus 2.8 visits; P ¼ 0:037) than the
standard care group.35 In this trial the direct costs
of pulmonary rehabilitation were more than offset
by reductions in subsequent healthcare utilisation.
Pulmonary rehabilitation—where to now?
In addition to the benefits already described,
indirect evidence suggests that pulmonary rehabi-
litation can extend survival, since dyspnoea,11
quality of life36 and functional status37 correlate
with survival, and it is clear that pulmonary
rehabilitation can provide improvements in these
parameters.2 Future research will focus on defini-
tively establishing whether rehabilitation can im-
prove survival, and developing the means to
maintain the benefits of rehabilitation—likely to
depend on behavioural changes. The other impor-
tant goal in the management of COPD, is to
increase the autonomy of patients with chronic
respiratory disease, through enhanced physical,
social and psychological function.
It will also be important to expand the use of
pulmonary rehabilitation, by providing increased
access to rehabilitation programmes. This can be
achieved by increasing the provision of resources
and services, by allowing patients to access
programmes earlier and more easily, and by further
developing the content of pulmonary rehabilitation
programmes. We should also extend the use of
pulmonary rehabilitation to include other forms of
chronic respiratory illness.Conclusions
While many questions remain unanswered, recent
years have witnessed an explosion in our knowledge
of how to characterise and treat patients with
COPD. The focus of future research must be to
further our understanding of the molecular basis of
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Future perspectives in COPD S47COPD and to determine how this relates to the
gross pathophysiological defects seen in these
patients. New treatments and the wider applica-
tion of individually designed treatments, such as
pulmonary rehabilitation, remain an important
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